Application of CUX2 as target in preparation of medicine for treating inflammatory bowel disease and intestinal barrier injury

By reducing CUX2 gene expression, repairing intestinal barrier function, and inhibiting NF-κB signaling pathway, the problem of intestinal barrier damage in inflammatory bowel disease is solved, providing a new treatment direction, and has important clinical application value.

CN118903422APending Publication Date: 2024-11-08浙江百越生物技术有限公司
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410935329.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The mechanism of intestinal barrier damage in the mid-inflammatory bowel disease (IBD) is not fully understood, and existing treatments are difficult to effectively repair the intestinal barrier, resulting in the continuous onset of inflammation.

Method used

By verifying the role of differentially expressed gene CUX2 under lipopolysaccharide induction, gene knockdown, gene silencing or chemical drugs are used to reduce CUX2 gene expression to repair intestinal barrier function, inhibit NF-κB signaling pathway, and develop targeted Treatment drugs for CUX2.

Benefits of technology

Reducing intestinal barrier damage, reducing inflammation, and inhibiting NF-κB signaling pathways provide new effective strategies for the treatment of inflammatory bowel disease and intestinal barrier damage, and has important clinical application value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903422A_ABST
    Figure CN118903422A_ABST
Patent Text Reader

Abstract

The invention discloses an application of CUX2 as a target in preparation of drugs for treating inflammatory bowel diseases and intestinal barrier injury, and an application of a CUX2 inhibitor in preparation of drugs for treating inflammatory bowel diseases and intestinal barrier injury. Researches show that lipopolysaccharide-induced intestinal barrier injury can be aggravated by increasing the expression of CUX2, and tight junction (TJ) protein can be up-regulated and an NF-kappa B signal channel can be inhibited by inhibiting CUX2, so that the LPS-induced intestinal barrier injury is repaired, and the inhibition of CUX2 may be an effective strategy for IBD treatment. New scientific research evidence is provided for research and development of drugs for treating inflammatory bowel diseases, a new treatment direction is provided for IBD patients, and important clinical application value and development value are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and in particular relates to an application of CUX2 as a target in the preparation of a drug for treating inflammatory bowel disease and intestinal barrier damage. Background Art

[0002] Inflammatory bowel disease (IBD) mainly includes two chronic idiopathic inflammatory diseases, namely ulcerative colitis (UC) and Crohn's disease, which are characterized by chronic relapsing intestinal inflammation. IBD poses a huge threat to public health, with increasing incidence and morbidity over the past few decades. IBD is a multifactorial disease involving dietary, microbial, environmental, immunological and genetic factors, but the exact etiology has not yet been fully explained. Nowadays, intestinal barrier dysfunction has become an indicator of the disease. When the intestinal barrier is damaged, intestinal permeability may increase, allowing bacteria and toxins to pass through the intestinal wall, which may lead to the occurrence of inflammatory bowel disease (IBD). Studies have shown that damage to the intestinal mucosal barrier function in patients with IBD is one of the key factors in the pathogenesis of the disease. Therefore, maintaining the integrity of the intestinal barrier is very important for the prevention and treatment of IBD.

[0003] Lipopolysaccharide (LPS) is an important component of the outer membrane and participates in host-pathogen interactions with the innate immune system. It is considered a key factor in causing mucosal and systemic inflammation in various intestinal and extraintestinal diseases, and it may initially disrupt epithelial cell barrier function. Therefore, studying LPS-mediated intestinal barrier damage will help to better understand the pathogenesis of IBD.

[0004] In the current study, RNAs that were abnormally regulated in the inflammatory and non-inflammatory mucosa of 5 UC patients and the mucosa of 5 healthy controls were shown in GSE 178753. The present invention attempts to study target genes in LPS-mediated intestinal barrier damage to develop drugs for the treatment of inflammatory bowel disease and intestinal barrier damage.

[0005] The CUX2 gene is highly expressed in inflamed mucosa compared with non-inflamed mucosa and healthy controls. CUX2 is closely related to various biological processes, such as cell cycle progression, apoptosis, and repair of oxidative DNA damage. It has been reported that CUX2 protein exhibits a limited expression pattern and plays a promoting or inhibiting role in transcriptional activity under different circumstances. However, the role of CUX2 in LPS-induced intestinal barrier damage is still unclear. Summary of the invention

[0006] The purpose of the present invention is to verify the specific impact of the differentially expressed gene CUX2 in lipopolysaccharide-induced intestinal barrier damage. Studies have shown that CUX2 can be used as a target to reduce the expression of the CUX2 gene through gene knockout, gene knockdown or silencing or chemical drugs, which can reduce intestinal barrier damage and be used to prepare drugs for the treatment of inflammatory bowel disease.

[0007] The technical solution adopted by the present invention is:

[0008] Application of CUX2 as a target in the preparation of drugs for the treatment of inflammatory bowel disease.

[0009] Furthermore, targeting CUX2 refers to reducing the expression of the CUX2 gene by gene knockout, gene knockdown, gene silencing or chemical drugs.

[0010] The drug for treating inflammatory bowel disease targets the CUX2 gene, can repair the intestinal barrier function, reduce inflammation, and inhibit the NF-κB signaling pathway.

[0011] Furthermore, the present invention provides the use of CUX2 as a target in the preparation of a drug for treating intestinal barrier damage. Intestinal barrier damage is a hallmark symptom of inflammatory bowel disease. Using CUX2 as a target, gene knockout, gene knockdown, gene silencing or chemical drugs to reduce the expression of the CUX2 gene can repair the barrier damage.

[0012] The present invention also provides use of a CUX2 inhibitor in preparing a drug for treating inflammatory bowel disease.

[0013] The present invention also provides use of a CUX2 inhibitor in preparing a drug for treating intestinal barrier damage.

[0014] Furthermore, CUX2 inhibitors are used in the preparation of drugs for repairing intestinal barrier function, reducing inflammation, and inhibiting NF-κB signaling pathways.

[0015] The CUX2 inhibitor refers to a substance that can reduce the expression level of the CUX2 gene, a substance that reduces the activity of the CUX2 protein and / or a substance that increases the metabolism of the CUX2 protein.

[0016] Furthermore, the CUX2 inhibitor can be one or more of a small interfering RNA (siRNA) of the CUX2 gene, an RNA interference vector of the CUX2 gene, an antibody of CUX2, and other inhibitors capable of inhibiting CUX2 expression, or various chemical substances capable of reducing the activity of the CUX2 protein and enhancing the metabolism of the CUX2 protein.

[0017] The present invention also provides a drug for treating inflammatory bowel disease, comprising a CUX2 inhibitor.

[0018] The present invention also provides a medicine for treating intestinal barrier damage, comprising a CUX2 inhibitor.

[0019] The beneficial effects of the present invention are:

[0020] The present study showed that increasing CUX2 expression can aggravate LPS-induced intestinal barrier damage, while reducing CUX2 expression can repair intestinal barrier damage. CUX2 regulates intestinal barrier damage by downregulating tight junction proteins and activating the NF-κB signaling pathway. Inhibiting CUX2 can upregulate tight junction (TJ) proteins and inhibit the NF-κB signaling pathway, thereby repairing LPS-induced intestinal barrier damage, indicating that inhibiting CUX2 may be an effective strategy for the treatment of IBD.

[0021] The present invention provides new scientific research evidence for the development of drugs for treating inflammatory bowel disease and a new treatment direction for IBD patients, and has important clinical application value and development value. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0023] Figure 1 The results of LPS induction, overexpression of CUX2 and knockdown of CUX2 on CUX2 are shown in Figure 1, where Figure A is a bar graph of CUX gene expression levels after LPS treatment; Figure B is a graph of CUX protein expression levels after LPS treatment; Figure C is a bar graph of CUX gene expression levels under different treatments of LPS, LPS+NC, LPS+overexpression of CUX2, LPS+shNC, and LPS+shCUX2; Figure D is a graph of CUX protein expression levels in different treatment groups;

[0024] ### represents relative to the control group, P<0.001; *** represents relative to the LPS group, P<0.001; ^^^ represents relative to the LPS+shNC group, P<0.001.

[0025] Figure 2The results of the effects of LPS treatment, overexpression of CUX2, and knockdown of CUX2 on TEER, FD4 flux, and TJ protein expression in Caco-2 cells are shown in Figure A, where Figure A is a graph showing the effects of different treatments on TEER values, Figure B is a bar graph showing FITC-FD4 flux in different groups, Figure C is a bar graph showing the gene expression levels of three TJ proteins, ZO-1, Occludin, and Claudin-3, and Figure D is a graph showing the protein expression levels of ZO-1, Occludin, and Claudin-3;

[0026] In the figure, ## represents P < 0.01, and ### represents P < 0.001 relative to the control group;

[0027] Relative to the LPS group, ** represents P < 0.01, *** represents P < 0.001;

[0028] Relative to the LPS+shNC group, ^^ represents P < 0.01, ^^^ represents P < 0.001.

[0029] Figure 3 The results of immunofluorescence detection of TJ protein expression in Caco-2 cells after LPS treatment, overexpression of CUX2, and knockdown of CUX2.

[0030] Figure 4 The figures show the effects of LPS treatment, overexpression of CUX2 and knockdown of CUX2 on inflammatory factors and NF-κB signaling pathways, among which, Figure A is a bar graph of IL-6 concentration in different treatment groups, Figure B is a bar graph of TNF-α concentration, Figure C is a bar graph of p-p65, p65, p-IκBα, and IκBα proteins, Figure D is a bar graph of the p-p65 / p65 ratio, and Figure E is a bar graph of the p-IκBα / IκBα ratio.

[0031] In the figure, ### represents P < 0.001 relative to the control group;

[0032] *** represents P < 0.001 relative to the LPS group;

[0033] Relative to LPS+shNC group, ^^^ represents P < 0.001. DETAILED DESCRIPTION

[0034] The technical solution of the present invention is further described below in conjunction with the embodiments. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar substitutions and modifications are obvious to those skilled in the art, and they are all deemed to be included in the protection scope of the present invention. The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the products described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention. The protection scope of the present invention is not limited to this.

[0035] Example 1 Application of the mechanism of CUX2 aggravating lipopolysaccharide-induced intestinal barrier damage

[0036] 1. Materials and Methods

[0037] 1. Cell Source and Culture

[0038] The human epithelial cell line Caco-2 (HTB-37) was used to establish the intestinal epithelial barrier model. Caco-2 cells were cultured in high-glucose DMEM medium. The medium was supplemented with 10% fetal bovine serum (FBS, C0227, Beyotime, Shanghai, China), 2% L-glutamine (G7513, Sigma-Aldrich, Missouri, USA) and 1% penicillin / streptomycin solution (15070063, Thermo Fisher, Massachusetts, USA). The culture conditions were 37°C, 5% CO2 and 95% air humidification conditions.

[0039] 2. Cell Treatment and Transfection

[0040] Caco-2 cells were treated with 10 μg / ml LPS for 24 h. Plasmids for overexpressing CUX2 (C05002), short hairpin RNA targeting CUX2 (shCUX2, C01001), and empty vector (NC, C05002; shNC, C01001) were provided by Genepharma (Shanghai, China). TM The cells were transfected with plasmids overexpressing CUX2, shCUX2, NC or shNC using 3000 transfection reagent (L3000015, Thermo Fisher, Massachusetts, USA).

[0041] 3.Quantitative real time polymerase chain reaction (qRT-PCR)

[0042] TRIzol reagent (93289, Sigma-Aldrich, Missouri, USA) was used to extract total RNA from Caco-2 cells. RNA concentration and purity were determined using a UV spectrophotometer (DR6000, HACH, Shanghai, China). TM 1 μg of RNA was reverse transcribed using IV reverse transcriptase (18090010, Thermo Fisher, Massachusetts, USA) to generate complementary DNA (cDNA). SYBR Premix Ex Taq II (RR820A, Takara, Japan) was used in CFX Connect TM qRT-PCR was performed on Real-Time PCR Detection System (1855201, Bio-Rad, California, USA). The primers for PCR amplification are as follows: CUX2 forward primer,5'-TTGGAAGCGATTTGATCTACGG-3'and reverse primer,5'-CCGGCGGAGTTCAATTAAATGT-3'; ZO-1 forward primer,5'-CAACATACAGTGACGCTTCACA-3'and reverse primer,5'-CACTATTGACGTTTCCCCACTC-3'; Occludin forward primer,5'-ACAAGCGGTTTTATCCAGAGTC-3'and reverse primer,5'-GTCATCCACAGGCGAAGTTAAT-3';Claudin-3forward primer,5'-AACACCATTATCCGGGACTTCT-3'and reverse primer,5'-GCGGAGTAGACGACCTTGG-3';glyceraldehyde-3-phosphatedehydrogenase(GAPDH)forward Primer, 5'-GGAGCGAGATCCCTCCAAAAT-3' and reverse primer, 5'-GGCTGTTGTCATACTTCTCATGG-3'. Relative expression was assessed by normalizing it to GAPDH using the 2-ΔΔct method.

[0043] 4. Western blot experiment

[0044] The expression of CUX2, TJ proteins (ZO-1, Occludin and Claudin-3), and proteins related to the NF-κB signaling pathway (phosphorylated (p)-p65, p65, p-IkappaBalpha (IκBα) and IκBα) in Caco-2 cells was detected by Western blot experiments. Caco-2 cells were lysed in RIPA lysis buffer (20-188, Sigma-Aldrich, Missouri, USA), and the amount of protein was determined using a BCA protein assay kit (7780S, CST, Boston, USA). Equal amounts of protein samples were electrophoresed in 10% SDS-PAGE, then transfected into polyvinylidene fluoride (PVDF) membranes (88585, ThermoFisher,) and blocked in 5% skim milk at room temperature for 1 h. The membrane was incubated with the following specific primary antibodies overnight at 4°C: CUX2 (TA342452, 162 kDa, 1:1000, ORIGENE), ZO-1 (#13663, 220 kDa, 1:1000, CST), Occludin (#91131, 65 kDa, 1:1000, CST), Claudin-3 (#83609, 20 kDa, 1:1000, CST), p-p6 5 (#3033, 65 kDa, 1:1000, CST), p65 (#8242, 65 kDa, 1:1000, CST), p-IκBα (ab92685, 36 kDa, 1:1000, Abcam), IκBα (ab97783, 36 kDa, 1:1000, Abcam), GAPDH (TA802519, 35.9 kDa, 1:2000, ORIGENE). After washing three times with TBST, the membrane was incubated with secondary antibodies Goat Anti-Rabbit IgG H&L (ab6721, 1:3000, Abcam) or Goat Anti-Mouse IgG H&L (ab6708, 1:3000, Abcam) at room temperature for 1 hour. Chemiluminescent substrate (34577, Thermo Fisher, Massachusetts, USA) was used to treat protein bands, which were then detected using the FluorChemM chemiluminescent imaging analysis system (Protein Simple, Silicon Valley, California, USA). Relative expression was normalized to GAPDH.

[0045] 5. Transepithelial electrical resistance (TEER) measurement

[0046] The Millicell-ERS system (MERS00002, Sigma-Aldrich, Missouri, USA) was used for measurement. The changes in TEER were measured using an epithelial volt-ohmmeter (World Precision Instruments, Sarasota, Florida, USA). After being corrected for membrane insertion, the values ​​are expressed in Ωcm2. When similar values ​​were obtained continuously, resistance measurements were performed every day for five days.

[0047] 6.4-kDa fluorescein isothiocyanate (FITC)-dextran (FD4) flux assay

[0048] The flux of FD4 (4013, Chondrex, Woodinville, Washington, USA) was measured to quantify the permeability of Caco-2 cell monolayer epithelium. 1 mg / ml FD4 was added to the apical chamber. After 2 hours of incubation, the culture medium was harvested from the basolateral chamber. A fluorescence microplate reader (5200220, Thermo Fisher, Massachusetts, USA) was used to quantify the fluorescence intensity of FITC, with an excitation wavelength of 460 nm and an emission wavelength of 520 nm.

[0049] 7. Immunofluorescence Staining

[0050] Caco-2 cells were stored in chamber slides (154461, Thermo Fisher, Massachusetts, USA). The cells were washed three times in phosphate buffered saline (PBS) for 5 minutes each time and then treated with 3.7% paraformaldehyde for 10 minutes. They were blocked for 1 hour with 10% bovine serum albumin (BSA, A1933, Sigma-Aldrich, Missouri, USA) and then permeabilized with 0.1% TritonX-100 (X100, Sigma-Aldrich, Missouri, USA). After washing, Claudin-3 (ab214487, 1:100, Abcam), Occludin (ab216327, 1:100, Abcam) and ZO-1 (ab221547, 1:100, Abcam) antibodies were used to incubate the cells overnight (4°C). The slides were incubated with FITC-conjugated secondary antibodies (ab6717, 1:1000, Abcam) for 45 min. DAPI was used to counterstain the nuclei. The images of the slides were captured under a fluorescence microscope (TE2000, Nikon, Tokyo, Japan) at a magnification of ×400.

[0051] 8. Enzyme-linked immunosorbent assay (ELISA)

[0052] The concentrations of inflammatory factors interleukin 6 (IL-6) and tumor necrosis factor-α (TNF-α) in Caco-2 cells were evaluated using ELISA kits (EH0201, EH0302, Fine Test, Wuhan, China). The absorbance of the samples was measured at 450 nm using a microplate reader (1215D29, Thomas Scientific, Swedesboro, New Jersey, United States).

[0053] 9. Statistical Analysis

[0054] Statistical analysis was performed using Graphpad 8.0 statistical software (Graphpad Software, California, USA). Data are expressed as mean ± standard deviation (mean ± SD). One-way analysis of variance (ANOVA) was used to determine the statistical significance of comparisons among multiple groups. P values ​​less than 0.05 were considered statistically significant.

[0055] 2. Experimental Results

[0056] 1. LPS promotes CUX2, overexpression of CUX2 enhances the effect of LPS on CUX2, while CUX2 knockdown has the opposite effect

[0057] To investigate the effect of LPS on CUX2 expression in Caco-2 cells, qRT-PCR and western blot experiments were performed. The results showed that the level of CUX2 increased significantly after LPS treatment ( Figure 1 Figures A and B, P<0.001). According to the results of qRT-PCR and Western blotting, the plasmid overexpressing CUX2 enhanced the promoting effect of LPS on CUX2 expression in Caco-2 cells, while shCUX2 reversed this effect ( Figure 1 C and D, P < 0.001). Therefore, these results indicate that LPS promotes the expression of CUX2 in Caco-2 cells, and CUX2 enhances the effect of LPS on CUX2.

[0058] 2. CUX2 promotes LPS-induced changes in TEER, FD4 flux, and TJ protein expression in Caco-2 cells, while CUX2 knockdown has the opposite effect

[0059] The effect of LPS on the ion permeability of Caco-2 cells was determined by measuring the TEER values ​​in the cell monolayer. The results showed that LPS treatment decreased the TEER values ​​( Figure 2Figure A, P<0.05). In addition, CUX2 overexpression further reduced the TEER value decreased by LPS, while shCUX2 transfection reversed the effect of LPS ( Figure 2 Figure A, P < 0.05). We then evaluated the permeability of the Caco-2 cell monolayer epithelium by measuring FITC-FD4 flux in the Caco-2 cell monolayer, and found that the LPS-increased FD4 flux was further enhanced by the CUX2 overexpression plasmid and was abolished by CUX2 knockdown ( Figure 2 Figure B, P<0.01). In addition, qRT-PCR and Western blot were used to examine the effects of LPS and CUX2 on TJ proteins in Caco-2 cells. We found that CUX2 overexpression further reduced the levels of TJ proteins, including ZO-1, Occludin, and Claudin-3, while shCUX2 reversed the effects of LPS ( Figure 2 C and D, P<0.01). Immunofluorescence results showed that the expression of ZO-1, Occludin and Claudin-3, which were inhibited by LPS treatment, was further inhibited by CUX2 overexpression. On the contrary, shCUX2 transfection offset the effect of LPS ( Figure 3 ). Taken together, the above findings indicate that overexpression of CUX2 promoted LPS-induced changes in TEER, FD4 flux, and TJ protein expression in Caco-2 cells, whereas knockdown of CUX2 abolished the above changes.

[0060] 3. CUX2 promotes LPS-induced changes in inflammatory factors and NF-κB signaling pathways in Caco-2 cells, while CUX2 knockdown has the opposite effect

[0061] After LPS treatment and transfection, the levels of inflammatory factors in Caco-2 cells were detected. ELISA showed that CUX2 overexpression enhanced the increase in IL-6 and TNF-α concentrations induced by LPS, while CUX2 knockdown reversed the effect of LPS on inflammatory factors ( Figure 4 In addition, LPS was found to increase the ratios of p-p65 / p65 and p-IκBα / IκBα in Caco-2 cells ( Figure 4 CE, P<0.001), indicating that LPS may promote intestinal barrier damage by activating the NF-κB signaling pathway. CUX2 overexpression further enhanced the effect of LPS in this pathway, while CUX2 silencing counteracted the effect of LPS ( Figure 4 CE, P<0.001). In conclusion, these experiments demonstrated that CUX2 promoted the changes of inflammatory factors and NF-κB signaling pathway in LPS-induced Caco-2 cells.

Claims

1. Application of CUX2 as a target in the preparation of drugs for the treatment of inflammatory bowel disease.

2. Application of CUX2 as a target in the preparation of drugs for the treatment of intestinal barrier damage.

3. The use according to claim 1 or 2, characterized in that: Targeting CUX2 refers to reducing the expression of the CUX2 gene by gene knockout, gene knockdown, gene silencing or chemical drugs.

4. Application of CUX2 inhibitors in the preparation of drugs for inflammatory bowel disease.

5. The use according to claim 4, characterized in that Application of CUX2 inhibitors in the preparation of drugs for repairing intestinal barrier function, reducing inflammation, and inhibiting NF-κB signaling pathway.

6. The use according to claim 4, characterized in that CUX2 inhibitors include substances that reduce the expression level of CUX2 gene, substances that reduce the activity of CUX2 protein and / or substances that increase the metabolism of CUX2 protein.

7. The use according to claim 6, characterized in that The CUX2 inhibitor includes one or more of small interfering RNA of CUX2 gene, RNA interference vector of CUX2 gene or antibody of CUX2 and other inhibitors capable of inhibiting CUX2 expression, or various chemical substances capable of reducing CUX2 protein activity and improving CUX2 protein metabolism.

8. A drug for treating inflammatory bowel disease, characterized in that: Including CUX2 inhibitors.

9. A drug for treating intestinal barrier damage, characterized in that: Including CUX2 inhibitors.

10. The drug according to claim 8, characterized in that The drug for treating inflammatory bowel disease targets the CUX2 gene, repairs the intestinal barrier function, reduces inflammation, and inhibits the NF-κB signaling pathway.